BioXcel Therapeutics (BTAI) Cash from Operations (2017 - 2026)

BioXcel Therapeutics has reported Cash from Operations for 10 years, with the latest figure at -$6.1 million in Q2 2026.

• On a quarterly basis, Cash from Operations rose 51.51% year-over-year to -$6.1 million in Q2 2026; TTM through Jun 2026 was -$50.9 million, a 8.72% increase from a year earlier, with the FY2025 full-year figure at -$57.6 million, up 20.01% from the prior year.
• Cash from Operations was -$6.1 million for Q2 2026 at BioXcel Therapeutics, up from -$11.8 million in the prior quarter.
• The five-year high for Cash from Operations was -$6.1 million in Q2 2026, with the low at -$52.4 million in Q1 2023.
• Average Cash from Operations over 5 years is -$24.3 million, with a median of -$21.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Cash from Operations plunged 93.85% in 2022, then surged 66.18% in 2024.
• Over 5 years, Cash from Operations stood at -$38.6 million in 2022, then jumped by 30.48% to -$26.9 million in 2023, then jumped by 44.87% to -$14.8 million in 2024, then climbed by 4.04% to -$14.2 million in 2025, then jumped by 57.09% to -$6.1 million in 2026.
• The last three Cash from Operations figures came in at -$6.1 million (Q2 2026), -$11.8 million (Q1 2026), and -$14.2 million (Q4 2025), per Business Quant data.